Genesis Healthcare, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended of June 30, 2016. For the quarter, the company reported net revenues of $1,438,358,000 compared to $1,419,475,000 a year ago. Loss before income tax expense was $32,933,000 compared to $37,633,000 a year ago. Loss from continuing operations was $36,019,000 compared to $33,214,000 a year ago. Net loss attributable to the company was $22,973,000 compared to $19,186,000 a year ago. Basic and diluted net loss per common share was $0.26 compared to $0.22 a year ago. EBITDAR was $205,848,000 compared to $181,316,000 a year ago. EBITDA was $168,880,000 compared to $142,357,000 a year ago. Adjusted EBITDAR was $189,352,000 compared to $197,974,000 a year ago. Adjusted EBITDA was $62,975,000 compared to $76,557,000 a year ago.

For the six months, the company reported net revenues of $2,910,576,000 compared to $1 2,762,476,000 a year ago. Loss before income tax expense was $100,859,000 compared to $161,643,000 a year ago. Loss from continuing operations was $107,009,000 compared to $151,576,000 a year ago. Net loss attributable to the company was $66,012,000 compared to $131,752,000 a year ago. Basic and diluted net loss per common share was $0.74 compared to $1.60 a year ago. Net cash provided by operating activities was $23,515,000 compared to net cash used in operating activities of $7,729,000 a year ago. EBITDAR was $372,184,000 compared to $274,971,000 a year ago. EBITDA was $297,900,000 compared to $199,593,000 a year ago. Adjusted EBITDAR was $367,702,000 compared to $375,777,000 a year ago. Adjusted EBITDA was $116,508,000 compared to $136,982,000 a year ago.

The company provided earnings guidance for the full year of 2016. For the period, the company expects net revenues to be in the range of $5,650 million to $5,750.0 million. Adjusted EBITDAR expected to be in the range of $710.0 million to $740.0 million. Adjusted EBITDA expected to be in the range of $208.0 million to $238.0 million.